Breaking News

Tweet TWEET

Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors

  Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of
                                  Directors

PR Newswire

ALISO VIEJO, Calif., March 19, 2014

ALISO VIEJO, Calif., March 19, 2014 /PRNewswire/ --Avanir Pharmaceuticals,
Inc. (NASDAQ: AVNR) today announced the appointment of Dr. Mark Corrigan to
the company's board of directors. Dr. Corrigan, a seasoned life sciences
executive joins Avanir's board with broad healthcare industry experience.

Avanir Pharmaceuticals, Inc.

Dr. Corrigan currently serves as president and chief executive officer of
Zalicus Inc. a public biopharmaceutical company, a position he has held since
January 2010. He has also served as a director of Zalicus and its progenitor
companies since December 2006. Prior to Zalicus, Dr. Corrigan served as
executive vice president, research and development at Sepracor, Inc. (now
known as Sunovion Pharmaceuticals, Inc.). Prior to joining Sepracor, Dr.
Corrigan spent 10 years with Pharmacia & Upjohn, a pharmaceutical company
acquired by Pfizer, Inc. in 2003, most recently as group vice president of
Global Clinical Research and Experimental Medicine. Prior to joining the
pharmaceutical industry, Dr. Corrigan spent five years in academic research at
the University of North Carolina Medical School, focusing on
psychoneuroendocrinology. Dr. Corrigan has also been a member of the board of
directors and audit committee of Cubist Pharmaceuticals, Inc. since June 2008.
Dr. Corrigan holds a B.A. and an M.D. from the University of Virginia and
subsequently received specialty training in Psychiatry at Cornell and Maine
Medical Center.

"It is a pleasure to welcome Mark to the Avanir Board," commented Craig
Wheeler, chairman of the board, "Mark brings many years of experience in the
healthcare sector combined with a deep knowledge of CNS research and
development together with broad experience in guiding the growth of biopharma
companies. I look forward to the insights he will bring to our board and to
working with him as Avanir pursues its growth initiatives."

About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc.is a biopharmaceutical company focused on
bringing innovative medicines to patients with central nervous system
disorders of high unmet medical need. As part of our commitment, we have
extensively invested in our pipeline and are dedicated to advancing medicines
that can substantially improve the lives of patients and their loved ones. For
more information about Avanir, please visitwww.avanir.com.

AVANIR^® is a trademark or registered trademark of Avanir Pharmaceuticals,
Inc. in the United States and other countries.

©2014 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com
+1 (949) 389-6700

Joey Fleury, BrewLife
jfleury@brewlife.com
+1 (415) 946-1090

Logo- http://photos.prnewswire.com/prnh/20130207/LA55901LOGO

SOURCE Avanir Pharmaceuticals, Inc.

Website: www.avanir.com
 
Press spacebar to pause and continue. Press esc to stop.